News -

Announcing the launch of iLite™ VEGF Assay Ready Cells

The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

The signaling protein Vascular Endothelial Growth Factor (VEGF) is a major contributor to angiogenesis in both health and disease. Since angiogenesis is required for tumour growth and metastasis, drugs targeting VEGF have been increasingly employed in a vast number of cancer therapies. In addition, anti-VEGF therapies have been successfully used for treating ophthalmologic indications and rheumatoid arthritis.

Since the functional activity of VEGF can be measured with the iLite™ VEGF Assay Ready Cells, these can be used for direct comparison of biosimilars and innovator drugs. The iLite™ VEGF Assay Ready Cells is the second in a long line of products for biosimilar comparisons coming this year, adding to the existing iLite™ TNF-α Assay Ready Cells. 

For more information, please see the iLite™ product page, and keep an eye out for the next iLite™ launch within inflammation - iLite™ IL-23 Assay Ready Cells!

Related links

Topics

  • Diseases

Categories

  • ilite cell-based assays
  • product

Contacts

Trine Österbye

VP Biopharma Solutions iLite Cell-based Assays +46 40 53 76 47
Media Content Panel
iLite™ Technology 3D picture
License:
© All rights reserved (allow download)
Download

Related content

Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.

New research on cell-based reporter gene iLite™ assays

The 10th International Congress on Autoimmunity is taking place in Leipzig, Germany April 6-10. The event provides an opportunity to hear about the hot topics in autoimmunity and discuss the newest therapeutic techniques and diagnostic tools as well as the most up-to-date research. We are happy to announce that we will hold a presentation relating to the use of a cell-based reporter gene assay.

Discover new iLite™ IL-23 Assay Ready Cells

We are happy to introduce the iLite™ IL-23 Assay Ready Cells offering significant benefits as compared to conventional IL-23 assays. Using the iLite™ IL-23 Assay Ready Cells, a rapid assay for the functional activity of IL-23, without cross-reactivity with IL-12, can easily be set-up. Results are obtained within 6 h.